• Login
    View Item 
    •   UMB Digital Archive
    • UMB Open Access Articles
    • UMB Open Access Articles
    • View Item
    •   UMB Digital Archive
    • UMB Open Access Articles
    • UMB Open Access Articles
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of UMB Digital ArchiveCommunitiesPublication DateAuthorsTitlesSubjectsThis CollectionPublication DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    Statistics

    Display statistics

    Understanding authorized generics-A review of the published clinical data.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Author
    Alderfer, Justine
    Hansen, Richard A
    Mattingly, T Joseph
    Date
    2021-04-08
    Journal
    Journal of Clinical Pharmacy and Therapeutics
    Publisher
    Blackwell Publishing
    Type
    Article
    
    Metadata
    Show full item record
    See at
    https://doi.org/10.1111/jcpt.13426
    Abstract
    What is known and objectives: Despite the large body of evidence demonstrating equivalent efficacy and safety for branded drugs and their generic counterparts, some patients and providers have the perception that generics may be less safe and effective than branded agents. Authorized generics (AGs) are a category of generic drugs defined by the United States Food and Drug Administration (FDA) as being the same as the brand-name drug without the brand’s name on the label and which may have minor differences, such as tablet or capsule markings for identification. Studies in which AGs are considered along with other generics may increase our understanding of factors that may influence perceptions about generics and shed light on areas where education may be impactful. The objectives of this paper are to provide information about AGs, review studies in which they have been evaluated and explore the role that AGs may fill in the individualized treatment of patients. Methods: A literature review was conducted on 30 September 2019 with follow-up search on 4 March 2020. The search was focussed on published papers and meeting abstracts that provided information on AGs with respect to medical and health outcomes of therapy as well as switching in individuals receiving branded, AG, or other generic agents. Information about patients’ perceptions of generic medications and adherence to therapy was also included. Additional information, including relevant government sources, such as the FDA website and the Federal Trade Commission Report, was included as appropriate. Results: The literature specific to AGs is limited, but available data clearly highlight the importance of patient perception of generics as well as medication appearance as factors that may affect adherence and potentially more frequent switchbacks to branded agents from generics or AGs. What is new and conclusion: To our knowledge, this is the first narrative review to provide a summary of the published evidence about AGs with respect to clinical and health outcomes and switching. There is a need for more research and education regarding the use of AGs in clinical practice if they are to become more recognized as a potential treatment choice for patients. Generic medications play an important role in the healthcare system, and AGs may be able to provide an option to meet the specific needs of individual patients.
    Rights/Terms
    © 2021 John Wiley & Sons Ltd.
    Keyword
    authorized generics
    Drugs, Generic
    Identifier to cite or link to this item
    http://hdl.handle.net/10713/15428
    ae974a485f413a2113503eed53cd6c53
    10.1111/jcpt.13426
    Scopus Count
    Collections
    UMB Open Access Articles

    entitlement

    Related articles

    • Comparative effectiveness of generic and brand-name medication use: A database study of US health insurance claims.
    • Authors: Desai RJ, Sarpatwari A, Dejene S, Khan NF, Lii J, Rogers JR, Dutcher SK, Raofi S, Bohn J, Connolly JG, Fischer MA, Kesselheim AS, Gagne JJ
    • Issue date: 2019 Mar
    • Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).
    • Authors: Rahman MM, Alatawi Y, Cheng N, Qian J, Plotkina AV, Peissig PL, Berg RL, Page D, Hansen RA
    • Issue date: 2017 Sep
    • Comparison of Generic-to-Brand Switchback Rates Between Generic and Authorized Generic Drugs.
    • Authors: Hansen RA, Qian J, Berg R, Linneman J, Seoane-Vazquez E, Dutcher SK, Raofi S, Page CD, Peissig P
    • Issue date: 2017 Apr
    • Retrospective Database Analysis to Explore Patterns and Economic Burden of Switchback to Brand After Generic or Authorized Generic Utilization.
    • Authors: Alderfer J, Aggarwal J, Gilchrist K, Alvir JMJ, Cook J, Park SH, Stephens JM
    • Issue date: 2022
    • Perceptions of and barriers to use of generic medications in a rural African American population, Alabama, 2011.
    • Authors: Sewell K, Andreae S, Luke E, Safford MM
    • Issue date: 2012
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Policies | Contact Us | UMB Health Sciences & Human Services Library
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.